Skip to main content
. 2008 Dec 16;94(3):861–868. doi: 10.1210/jc.2008-1862

Table 1.

PCT, CT, and CEA levels in the study groups

Mean PCT ng/ml Median PCT ng/ml PCT positive levels Mean CT pg/ml Median CT pg/ml CT positive levels Mean CEA ng/ml Median CEA ng/ml CEA positive levels
Active MTC
 Newly diagnosed 13.8 5.2 8/8 1336.0 777.5 8/8 53.1 17.8 8/8
 Recurrent/metastatic 241.7 13.1 42/43 20447.9 3403.0 42/43 435.5 32.7 26/30
 Stable 3.3 0.6 33/40 334.7 78.0 40/40 19.2 3.7 18/32
Cured MTC <0.1 <0.1 0/42 5.5 <5.0 1/42 3.5 1.3 3/30
Follicular cell-derived carcinomas 0.1 <0.1 3/55 <5.0 <5.0 0/55 NT NT NT
Benign thyroid illnesses 0.1 <0.1 1/57 <5.0 <5.0 0/57 NT NT NT
Athyroid <0.1 <0.1 0/120 <5.0 <5.0 0/120 NT NT NT
Neuroendocrine tumors 0.17 <0.1 22/225 16.2 <5.0 8/225 NT NT NT
Mastocytosis <0.1 <0.1 2/48 6.1 <5.0 2/48 NT NT NT
Healthy donors <0.1 <0.1 1/197 5.2 <5.0 0/197 NT NT NT

NT, Not tested.